lamivudine studies
Select the study ID number to view the trial summary
| Study ID | Phase | Title |
| 105698 | IV | A post-marketing surveillance to monitor the safety of Zeffix(Lamivudine) administered in Korean chronic hepatitis B virus infection subjects according to the prescribing information |
| EPV40001 | IV | Open-Label, Pilot Study To Explore The Early Antiviral Activity And Tolerability Of Abacavir And Epivir When Each Is Administered Once-Daily Within A Triple Combination Regimen Including Abacavir, Epivir And Retrovir Compared to The Triple Combination Regimen Administered Twice-Daily In Antiretroviral Naïve, HIV-1 Infected Subjects (48 Week Report). |
| KOREA105816 | IV | A post-marketing surveillance to monitor the safety of 3TCTM (Lamivudine 150mg) administered in Korean subjects according to the prescribing information |
| LAMPOL 4001 | IV | Multicentre, open study to determine the effect of Lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection |
| LAMPOL 4003 | IV | Open study to determine the effect of Lamivudine on liver histology and DNA HBV suppression in patients after seroconversion in HBeAg and with HBsAg present |
| LAMPOL4002 | IV | A multicentre, open study to estimate the effect of Lamivudine on liver histology and HBV DNA clearance in patients with chronic hepatitis B |
| NUC30925 | IV | An open-label, Phase-IV study to demonstrate the efficacy and safety of locally manufactured (Suzhou, China) Lamivudine tablets (100mg) in Chinese patients with chronic hepatitis B (CHB) |
| NUC30937 | IV | An open label one year study of lamivudine in patients with chronic hepatitis. |
| NUC30944 | IV | A study of the safety and efficacy of Lamivudine 100 mg QD in patients with HBeAg negative (presumed pre-core mutant) chronic hepatitis B virus infection. |
| NUC30956 | IV | An Open Study of Lamivudine Treatment in Adult HBeAg Negative (presumed pre-core mutant) Chronic Hepatitis B genotype D Patients in Iran. |
| NUC40019 | IV | An open study to determine the safety and efficacy of lamivudine in subjects with chronic hepatitis B |
| NUC40021 | IV | A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint |
| NUC40032 | IV | Pre-emptive Lamivudine and Chemotherapy-induced Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies |
| NUC40036 | IV | An open-label, Phase IV study to examine whether the duration of lamivudine treatment following HBeAg seroconversion affects the durability of the HBeAg seroconversion response in Asian patients. |
| NUC40040 | IV | An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment |
| WE066, EPI40007 | IV | The Antiretroviral Pregnancy Registry (APR, Registry) |
| WE490 | IV | Lactic acid levels in children prenatally and perinatally treated with antiretrovirals to prevent HIV transmission. |
| ADF30003 | III | Clinical Evaluation of Adefovir Dipivoxil (GW284873X) in Patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy – A follow-up long term study of ADF30002 (a 16 week open label study). |
| LAM-EG-18 (NUC30933) | III | A Study of the Safety and Efficacy of Lamivudine 100 mg OD in Egyptian Patients with Chronic Replicating Hepatitis B Virus (CHB). |
| LB-02 | III | Phase III Study of Lamivudine - A Placebo-controlled, Double-blind Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-02) |
| LB-03 | III | Phase III Study of Lamivudine - A Long-term Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-03) |
| LB-04 | III | Phase III Clinical Trial of GG714 (Lamivudine): Histological Evaluation of Long-term Treatment - A Full Report of Extension Study - (Protocol No. LB-04) |
| LB-06 | III | Phase III Study of Lamivudine - Follow-up Investigation after Double-blind Study (LB-02) and Long-term Study (LB-03) - (Protocol No.: LB-06) |
| NUC30902 | III | A multicenter, prospective, descriptive study to compare the efficacy of lamivudine alone versus lamivudine plus anti-HB hyperimmune gammaglobulin in the prevention of hepatitis B virus reinfection after liver transplant. |
| NUC30903 | III | A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of 52 Weeks Lamivudine Treatment at a Dose of 3 mg/kg in Paediatric Subjects with Chronic Hepatitis B |
| NUC30907 | III | A randomized, double-blind, placebo-controlled study of the treatment of HBsAg positive patients after stable renal transplantation with lamivudine |
| NUC30914 | III | A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV. |
| NUC30926 | III | An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies |
| NUC30928 (NUCPT01) | III | A multicentre, single-arm, non-randomised trial to evaluate the efficacy and safety of lamivudine 100mg once a day in patients with chronic hepatitis B virus infection. |
| NUC30935 | III | A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV |
| NUC30958 (714LC-02) | III | A Phase III Clinical Study of GG714 (Lamivudine) Tablet -A study of extended GG714 treatment for subjects with hepatitis B-related Cirrhosis (long-term study) |
| NUC40040 | III | An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment |
| NUCA/B3016 | III | A Five Year Final Study Report for NUCA/B3016 - A Long-Term Epidemiologic Study of Subjects Who Have Evidence of Possible Durable Response to Lamivudine in Phase II or Phase III Trials of Lamivudine |
| NUCA2010/LAM-COMP | III | Lamivudine Compassionate Use for Patients with Decompensated Liver Injury Secondary to Hepatitis B Infection |
| NUCA3002 | III | A Randomized 3TCTM, ddC Double-Blind (ZDV Open-labeled) Multi-center Trial to Evaluate the Safety and Efficacy of 3TCTM (low dose) Administered Concurrently with Zidovudine (ZDV) versus 3TCTM (high dose) Administered Concurrently with ZDV Versus Dideoxycytidine (ddC) Administered Concurrently with ZDV in the Treatment of HIV-1 Infected ZDV-experienced (?24 Weeks) Patients with CD4 Cell Counts of 100/mm3 to 300/mm3. |
| NUCA3010 | III | A Study of Lamiviudine or Placebo in Patients with Chronic Hepatitis B Infection Who are Treatment Naive |
| NUCA3021 | III | Lamivudine Compassionate Use Treatment Program for Subjects with Three Life-Threatening Forms of Hepatitis B Infection |
| NUCAB3011 | III | A Placebo Controlled Study of Lamivudine and Intron A® in Patients with Chronic Hepatitis B Infection Who are Interferon a Non-Responders |
| NUCAB3017 | III | A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials |
| NUCB2015 | III | A Study of the Immunobiology of Patients with Chronic Hepatitis B Infection Treated with Lamivudine. Extensive searching has revealed that no clinical study report is available for this study. The Clinical trial results were reported via publication; see citation below. |
| NUCB3001 | III | A Randomized, Controlled 3TCTM Double-Blinded Trial to Compare the Safety and Efficacy of 3TCTM in Combination with Zidovudine (ZDV) Versus Zidovudine Monotherapy in Treating HIV-1 Infected Patients Who Are Zidovudine Therapy-Naïve With a CD4 Cell Count Between 100 - 400 cells/mm3. |
| NUCB3002 | III | A Randomized, Controlled, Lamivudine (3TCTM) Double-Blinded Trial to Compare the Safety and Efficacy of Zidovudine (ZDV) Monotherapy Versus Lamivudine Plus ZDV in Combination in Treating HIV-1 Infected Patients who are Zidovudine Therapy-Experienced With a CD4+ Cell Count Between 100cells/mm3 to 400cells/mm3 |
| NUCB3007 | III | A Randomized, Controlled, Double-Blinded, Clinical End-Point Trial to Compare the Efficacy and Safety of 3TC Versus 3TC + Loviride Versus Placebo in the Treatment of HIV-1 Infected Persons Taking Concurrent Zidovudine-Containing Treatment Regimens With CD4 Counts Between 25cells/mm3 to 250cells/mm3 |
| NUCB3009 | III | A Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Two Dosage Regimens of Lamivudine in Patients with Chronic Hepatitis B Infection |
| NUCB3010 | III | A Study of Lamivudine and Alpha-Interferon in Patients with Chronic Hepatitis B Infection Who are Interferon Treatment Naive |
| NUCB3014 | III | A Study of Lamivudine in Patients With HBeAb Positive Chronic Hepatitis B Infection; Week 52 (End of Treatment) Analysis |
| NUCB3018 | III | A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up) |
| NUCB3026 | III | A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment |
| NUCB4006 | III | A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis |
| ZEFT01 | III | A double blind randomised multicentre study of lamivudine added to the current treatment in the therapy of chronic hepatitis B in HBV-DNA/anti-HBe positive Subjects. |
| ZEFT02 | III | Open-label study of lamivudine in combination with interferon in treating chronic hepatitis B, anti HBe positive patients who are interferon-therapy naïve. |
| ZEFT03 | III | Open label treatment with lamivudine in patients with chronic hepatitis B, Anti HBe (Hepatitis B envelope) Positive, who have not responded to previous treatment with interferon. Study of lamivudine added to the interferon treatment in comparison to the sequential treatment |
| COLA4005 | II | A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of EPIVIR 150mg Twice-Daily Versus EPIVIR 300mg Once-Daily When Administered for 24 Weeks in Combination with FDA-Approved Dosage Regimens of ZERIT and Either CRIXIVAN or VIRACEPT in Subjects with HIV-1 Infection |
| EPV20001 | II | A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg QD vs Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg QD in Antiretroviral-Naïve Adults with HIV-1 Infection. 48-Week Report |
| LB-01 | II | Dose Finding Study on Lamivudine in Chronic Hepatitis B Patients (Protocol LB01) |
| M00026/012 | II | An open, randomised, multicentre, phase II study to evaluate the safety and therapeutic efficacy of an investigational vaccination regimen versus Lamivudine in adult patients with HBeAg positive chronic Hepatitis B. Lamivudine (Lam): GlaxoSmithKline (GSK) Biologicals’ cytosine nucleoside analogue with anti-HIV and anti-hepatitis B activity. HBeAg: hepatitis B e antigen; HIV: human immunodeficiency virus. |
| NUC20904 | II | A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine |
| NUC20905 | II | A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus |
| NUC20912 | II | A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B |
| NUC20917 | II | A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904 |
| NUC30910 | II | Lamivudine for Prevention of HBV Reactivation in HBsAg Seropositive Patients undergoing Cytotoxic Chemotherapy |
| NUCA2005 | II | A phase I/II study to evaluate the safety, toxicity and preliminary efficacy of combinations of lamivudine (3TC), Zidovudine (ZDV) and Didanosine (ddI) in children with HIV infection. |
| NUCA2006 | II | A Pilot Study to Assess the Safety and Efficacy of Lamivudine During the Course of Liver Transplantation for Patients with Chronic Hepatitis B Infection |
| NUCA2008 | II | A Continuation Study of Lamivudine in Patients with Chronic Hepatitis B Infection |
| NUCA3001 | II | A Randomized, Double-Blind, Multi-center Trial to Compare the Safety and Efficacy of 3TCTM Monotherapy Versus Zidovudine (ZDV) Monotherapy Versus 3TCTM Administered Concurrently with ZDV in the Treatment of HIV-1 Infected Patients who are ZDV-Naïve (=4 weeks) with CD4 Cell Counts of 200-500 cells/mm3 |
| NUCA3005 | II | Lamivudine Open-label Protocol for Treatment of Patients with Hepatitis B Viral Infection After Liver Transplantation |
| NUCB2001 | II | A phase I/II study of the safety, pharmacokinetics and preliminary activity of 3TC (GR109714X) in HIV-positive, asymptomatic and mild ARC patients. |
| NUCB2002 | II | A Randomized, Multicentre, Single-blind (Patient), Placebo-controlled, Phase II, Dose-ranging Study to Determine the Pharmacokinetics, Safety and Preliminary Activity of Once Daily Lamivudine in Patients with Chronic Hepatitis B Infection |
| NUCB2003 | II | A Randomized, Multicentre, Single Blind (Patient) Study to Compare the Efficacy and Safety of 25 mg, 100 mg, and 300 mg Lamivudine, Once daily in patients with Chronic Hepatitis B Infection |
| NUCB2004 | II | A Randomized, Phase II, Single-blind (Patient), Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection |
| NUCB2005 | II | A Randomised, Phase II, Single-blind (Patient) Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection |
| NUCB2007 | II | A Double-blind, Placebo-controlled, Randomised, Parallel Group, Multicentre Study to Assess the Effect of Lamivudine on the Safety, Tolerability and Pharmacokinetics of Alpha-interferon in Patients Receiving Interferon for Chronic Hepatitis B Infection |
| NUCB2008 | II | An Open, Multicentre Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of Lamivudine in Chronic Hepatitis B Patients in End Stage Liver Failure Undergoing Liver Transplantation |
| NUCB2010 | II | An Open Phase II Pilot Study to Determine the Safety and Activity of Lamivudine in Patients with Chronic Hepatitis C Infection |
| NUCB2013 | II | An Open, Randomised, Multicentre Study to Compare the Safety and Efficacy of Lamivudine Versus Hepatitis B Immunoglobulin in the Prevention of Hepatitis B Reinfection After Liver Transplantation |
| NUCB2014 | II | Multicentre, Open Label Compassionate Use Programme for Patients Treated with 100 mg Lamivudine Once Daily for up to 5 Years |
| NUCB2018 | II | The Pharmacokinetics of Epivir (Lamivudine) When Co-Administered With Retrovir (Zidovudine) to HIV-1 Infected Pregnant Women and Their Offspring |
| NUCB2020 | II | A Phase II, Dose Ranging Study of the Pharmacokinetics of Lamivudine in Children and Adolescents with Chronic Hepatitis B Virus Infection |
| NUCB2021 | II | An Open, Single Centre Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of Lamivudine in Chronic Hepatitis B Patients in End Stage Liver Failure (ESLF) Undergoing Liver Transplantation |
| C93-015 | I | A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients with Impaired Hepatic Function |
| EPV10001 | I | An Open-Label, Randomized, 2-way Cross-over Study to Compare the Steady-State Pharmacokinetics of Lamivudine and Lamivudine Triphosphate Following Lamivudine 300mg Once Daily Versus EPIVIR 150mg Twice a Day in Healthy Volunteers |
| LB-05 | I | Comparison of Pharmacokinetic of Lamivudine Between Elderly Volunteers and Healthy Young Male Volunteers (Protocol LB-05) |
| M00026/016 | I | An open, randomised, multicentre, phase I/II study to evaluate the safety and therapeutic efficacy of an investigational vaccination regimen versus Lamivudine, in adult patients with HBeAg negative, anti-HBe antibody positive chronic Hepatitis B. Lamivudine (Lam): GlaxoSmithKline (GSK) Biologicals’ cytosine nucleoside analogue with anti-HIV and anti-hepatitis B virus (anti-HBV) activity. HBeAg: hepatitis B e antigen; HIV: human immunodeficiency virus. |
| NUC10901 | I | An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure |
| NUC10902 | I | A randomized, open-label, cross-over study in Chinese healthy subjects, to establish bioequivalence between two formulations of Lamivudine (GR109714X) clinical trail material |
| NUC10905 | I | A randomised, open label, cross-over study in Chinese healthy subjects, to establish bioequivalence between lamivudine oral solution and tablet (GR109714X) clinical trial material. |
| NUCA1004 | I | A Single-Dose Study of GR109714X (3TCTM) in HIV-Infected Patients with Impaired Renal Function |
| NUCA1006 | I | Bioequivalence of Lamivudine [GR109714X, 3TCTM] 75mg, 100mg, and 300mg Tablets in Asymptomatic HIV-Infected Male Patients |
| NUCA2002 | I | A Phase I/II Study of 3TC (GR109714X) in Children With HIV Infection |
| NUCB1002 | I | A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients With Impaired Hepatic Function (Protocol No: C93-015) |
| NUCB1003 | I | A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) Following Oral Dosing in Subjects With Impaired Renal Function |
| NUCB1004 (C93-086) | I | A study to investigate the comparative bioavailability of two oral formulations of GR109714X (Lamivudine). |
| NUCB1007 | I | A Study to Investigate the Pharmacokinetic Interaction Between Lamivudine and Alpha-Interferon in Healthy Subjects |
| NUCB1009 | I | A study to investigate the pharmacokinetics of lamivudine (GR109714X) in healthy male and female Chinese subjects. |